Premium
GSH ‐responsive polyglutamic acid nanocarriers for dual targeted cancer therapy
Author(s) -
Li HeYi,
Jing Fangkun,
Hao JunFeng
Publication year - 2020
Publication title -
journal of applied polymer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.575
H-Index - 166
eISSN - 1097-4628
pISSN - 0021-8995
DOI - 10.1002/app.49339
Subject(s) - polyglutamic acid , nanocarriers , mesoporous silica , biocompatibility , endocytosis , chemistry , drug delivery , dendrimer , doxorubicin , nanoparticle , nanocages , cancer therapy , nanotechnology , glutathione , internalization , biophysics , materials science , cancer , biochemistry , mesoporous material , chemotherapy , organic chemistry , medicine , surgery , cell , catalysis , biology , enzyme
In order to reduce the toxic side effects of chemotherapeutic drugs and improve the targeting and efficiency of cancer treatment, the development of drug delivery system has received great attention. In this study, second generation polyglutamic acid dendrimers (G 2 ) are used as basic materials to produce porous nanoparticles through cross link by crosslinkers containing disulfide bonds. The crosslinked products (G 2 ) n have negative electricity and abundant voids, which enable them to adsorb the electronegative anticancer drug DOX. At the same time, in order to transport DOX to the tumor site, we modified FA on DOX and encapsulated it in magnetic mesoporous silica (FA‐DOX‐MSNs). Therefore, the final nanoparticles (FA‐DOX‐MSNs/(G 2 ) n ) not only have dual targeting ability to transport DOX to the tumor site, but also have reductive responsiveness that can release drugs responsively in the tumor cells. In addition, it has good biocompatibility and endocytosis ability.